Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 209 clinical trials
Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)

/ISL to achieve 0.5 log10 decrease in HIV-1 ribonucleic acid (RNA) from study baseline (Day 1) to Day 8 is superior to placebo, each given in combination with failing antiretroviral therapy (ART).

  • 117 views
  • 05 Aug, 2021
  • 102 locations
Strengthening Families Living With HIV in Kenya

This study seeks to use a group-based microfinance/internal lending model to develop social capital among people with HIV in Kenya. This will create a context to deliver validated curriculum targeting intimate partner violence, positive parenting, agriculture, small business entrepreneurship, group-interpersonal therapy, and other determinants of well-being and ART adherence among …

violence
HIV Vaccine
  • 0 views
  • 19 Jul, 2021
  • 1 location
Dolutegravir and Darunavir Evaluation in Adults Failing Therapy

DEFT is a randomised, open-label study in HIV-1 infected patients failing first-line antiretroviral therapy (ART). The study compares 2 regimens of second-line ART (dolutegravir and darunavir

antiretroviral therapy
HIV Vaccine
darunavir
antiretroviral
reverse transcriptase inhibitor
  • 1172 views
  • 25 Mar, 2021
  • 32 locations
Bidirectional Upbeat Communication and Differentiated Distanced Care for Young People

estimates that only 49% of adolescents (aged 10-19 years) entering care from 2005-2016 have initiated antiretroviral therapy (ART). In response to the SARS-CoV-2 pandemic the South African government has

  • 0 views
  • 13 Mar, 2021
  • 1 location
Reducing HIV-related Stigma in School Children in Northern Uganda

, anticipated, courtesy, and perceived stigma (primary outcomes); HIV testing frequency among sexually active participants; linkage to care, antiretroviral therapy (ART) initiation and adherence among HIV

  • 0 views
  • 17 Jul, 2021
  • 1 location
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Ages 4 Weeks to <12 Years and <45 kg (MK-1439-066)

, who are treatment-naive (TN) or have been virologically suppressed (VS) on stable combination antiretroviral therapy (cART) for 3 months with no history of treatment failure. The first primary

lamivudine
antiretroviral therapy
HIV Vaccine
tenofovir
hiv-1 rna measurement
  • 0 views
  • 25 Jul, 2021
  • 14 locations
Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study

called antiretroviral therapy or ART, if they get HIV. This study will evaluate the viral and immune system responses in an Analytical Treatment Interruption (ATI), in participants who received VRC01 or

antiretroviral therapy
HIV Vaccine
hysterectomy
hiv test
immune globulin
  • 0 views
  • 31 Jul, 2021
  • 11 locations
Community Based Interventions to Improve HIV Outcomes in Youth: a Cluster Randomised Trial in Zimbabwe

A cluster randomised trial to determine the impact of an integrated community-based package of HIV services incorporating HIV testing, linkage to care and ongoing adherence support, combined with sexual and reproductive health (SRH) services and general health counselling for 16 to 24 year olds on population level HIV viral load …

hiv viral load
hiv test
HIV Vaccine
  • 0 views
  • 23 Jan, 2021
  • 3 locations
VITAL Start: Brief Facility-based Video Intervention

This a multi-center, parallel group, randomized controlled outcome assessor blinded trial with a qualitative descriptive component that seeks to assess the effectiveness of a brief facility-based video intervention to optimize retention and adherence to ART among pregnant and breastfeeding women with HIV infection.

HIV Infection
  • 3 views
  • 15 Feb, 2021
  • 1 location
ADAPT for Adolescents Adolescents

Adolescents and young adults (AYA) with HIV face unique challenges to engagement in care and their ability to achieve optimal health outcomes. The investigators hypothesize that developmentally-tailored behavioral interventions will improve engagement in HIV care and viral suppression among AYA with HIV in Kenya. This two stage study will initially …

  • 0 views
  • 29 Jun, 2021
  • 1 location